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Abstract Gas chromatography-mass spectrometry was used to
measure the oxidative DNA damage in diabetic subjects and
controls. Levels of multiple DNA base oxidation products, but
not DNA base de-amination or chlorination products, were found
to be elevated in white blood cell DNA from patients with type II
diabetes as compared with age-matched controls. The chemical
pattern of base damage is characteristic of that caused by an
attack on DNA by hydroxyl radical. An increased formation of
the highly reactive hydroxyl radical could account for many of
the reports of oxidative stress in diabetic subjects. There was no
evidence of an increased DNA damage by reactive nitrogen or
chlorine species.
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1. Introduction
The vascular and other complications of diabetes mellitus
are frequently suggested to involve oxidative damage resulting
from the hyperglycaemia and/or hyperlipidaemia. For exam-
ple, decreased levels of antioxidants (especially ascorbate) and
increased levels of lipid peroxidation products, such as F2-
isoprostanes, have been reported in diabetic patients (prior
to the onset of complications) by several groups [1^4]. Free
radicals and other reactive oxygen species can also often dam-
age DNA [5^8]. Guanine is the most oxidisable base in DNA
and increases in the levels of its oxidation product 8-hydroxy-
2P-deoxyguanosine (8OHdG) have been reported in mononu-
clear cells from patients with both insulin- and non-insulin-
dependent diabetes [9]. This was paralleled by an increased
DNA strand breakage in these cells [10]. An increased urinary
excretion of 8OHdG has also been reported [11] in diabetic
subjects. Urinary 8OHdG excretion is believed to result from
the repair of oxidative damage to DNA and its nucleotide
precursor pool [11].
Rises in 8OHdG in DNA can be produced by the attack of
several di¡erent reactive oxygen species, including hydroxyl
radical (OHc), singlet oxygen, certain peroxyl radicals and
(to a limited extent) peroxynitrite, ONOO3 [6,12,13]. Peroxy-
nitrite is a cytotoxic species generated when superoxide rad-
icals (O2c3) combine with nitric oxide and its formation has
been implicated in both the origin [14] and in the progression
[15] of diabetes. However, an attack of these di¡erent species
on DNA can be distinguished by the pattern of damage that is
caused to the other DNA bases. For example, OHc produces a
multiplicity of products from all four DNA bases, whereas
singlet oxygen is selective for guanine [6,8,12,16]. Peroxynitrite
generates mainly base de-amination and nitration products
(e.g. xanthine from guanine, hypoxanthine from adenine)
and 8OHdG is only a minor product [13,17]. Hypochlorous
acid (HOCl), a reactive species produced by the enzyme mye-
loperoxidase in isolated neutrophils, produces pyrimidine ox-
idation and chlorination products in DNA rather than
8OHdG [18].
In the present paper, we have identi¢ed the species most
likely to be responsible for the increased levels of oxidative
DNA damage in patients with type II diabetes by examining
the molecular pattern of damage to all four DNA bases using
gas chromatography-mass spectrometry (GC-MS) [8,19]. The
pattern of damage observed is exactly that expected from
OHc.
2. Materials and methods
2.1. Patients
Non-insulin-dependent diabetic patients (17 males, 21 females,
55.4 þ 6.6 years) were recruited from well-characterised patients at-
tending the Coimbra University Hospital’s Ophthalmology and En-
docrinology services. Healthy age-matched controls (9 males, 27 fe-
males, 50.7 þ 15.2 years) were recruited from the Institute sta¡ and
from the University for the elderly, Coimbra. None of the subjects
was taking antioxidant supplements. This study was approved by the
Ethics Committee of Coimbra University Hospitals.
2.2. Sample collection
Blood was collected by venipuncture into sampling vials (10 ml)
containing lithium-heparin. The samples were centrifuged at
2000Ug for 10 min at room temperature. Blood cells including the
bu¡y layer were transferred into new containers and were stored at
370‡C until analysis.
2.3. Reagents
Unless otherwise stated, chemicals were of the highest quality avail-
able from Sigma Chemical (Poole, Dorset, UK), BDH Chemical (Gil-
lingham, Dorset, UK) or Aldrich (Milwaukee, WI, USA). Ribonu-
cleases A (bovine pancreas, molecular biology grade) and T1
(Aspergillus oryzae) were from Sigma. 8-Hydroxyadenine, thymine
glycol and FAPy-guanine were synthesised as described in [20]. 2-
Hydroxyadenine, 5-hydroxycytosine and 5-hydroxymethyl hydantoin
were gifts from Dr. Miral Dizdaroglu (NIST, Gaithersburg, USA).
Other reagents needed for GC-MS were obtained as described in [19].
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2.4. DNA isolation
DNA isolation was carried out as described in John et al. [21] with
the modi¢cations described in [22]. The DNA was treated with a
mixture of RNases A and T1 to remove the RNA contamination [22].
2.5. Analysis of DNA base damage
This was performed essentially as described in [23] with the mod-
i¢cations described in [19]. Derivatisation was carried out at room
temperature in the presence of ethanethiol, a protocol which prevents
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Fig. 1. Levels of DNA base damage products in diabetic and control DNA. A: Pyrimidine oxidation products, B: purine oxidation products,
C: base deamination (xanthine, hypoxanthine) and chlorination (5-chlorouracil) products, D: total oxidative DNA damage. Results are
mean þ S.D. *Signi¢cant di¡erence, unpaired t-test at 99% con¢dence level.
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artifactual further oxidation of DNA bases during sample processing
[19].
3. Results
DNA was isolated from blood samples taken from type II
diabetic patients and age-matched controls. The DNA was
freed of RNA, hydrolyzed in acid, the base products con-
verted to volatile derivatives, separated by GC and the prod-
ucts analysed by MS. Precautions were taken throughout to
prevent any artifactual oxidation of undamaged DNA bases
[19,22,24]. The advantage of GC-MS analysis of oxidative
DNA damage is that it allows the simultaneous quantitation
of a wide range of DNA base damage products, including
8-hydroxyguanine [8]
Fig. 1 summarises the data obtained. There was no signi¢-
cant rise in 5-chlorouracil (C), a marker of the attack of
HOCl on cytosine residues in DNA [18]. Similarly, levels of
the base de-amination products hypoxanthine and xanthine
did not increase (C). The levels of 8-hydroxyguanine were
elevated (B), as expected from previous reports [9,11]. How-
ever, levels of 5-OH uracil, 5-OH methyluracil, thymine gly-
col, 5-OH methylhydantoin, 5-OH hydantoin, 5-OH cytosine,
2-OH adenine, 8-OH adenine and FAPy-adenine were also
elevated. Only FAPy-guanine remained unchanged. The total
of DNA base oxidative damage products was approximately
doubled (Fig. 1D).
4. Discussion
Our data show that the levels of products generated by
oxidative damage to all four DNA bases (cytosine, adenine,
guanine and thymine) are markedly elevated in total blood
cell DNA from patients with type II diabetes mellitus. This
is exactly the pattern one would expect from an attack of OHc
upon DNA [6,8,12]. This highly reactive free radical species
can cause damage to many biomolecules (reviewed in [25])
and its apparent generation in excess in diabetes could ac-
count for much of the oxidative damage to various biomole-
cules that has been described in previous papers [1^4]. Since
many DNA base oxidation products are mutagenic and/or
block the DNA replication [5,7], our data have implications
when considering the possibility of an elevated risk of cancer
development in diabetic subjects [26^28]. We obtained no evi-
dence for an increased attack upon DNA by HOCl or by
ONOO3 or other nitrogen-related species, since levels of
chlorouracil, xanthine or hypoxanthine were not increased.
Of course, these species might still be formed in excess in
diabetes, but attack other molecular targets.
Our data show one anomalous feature, in that levels of
FAPy-guanine were not increased (Fig. 1). When OHc attacks
guanine in DNA, both 8-hydroxyguanine and FAPy-guanine
are normally produced. The initial product of addition, 8-hy-
droxyguanine radical, has to undergo one electron oxidation
to generate 8-hydroxyguanine or reduction processes to gen-
erate FAPy-guanine [29]. The fact that only the former prod-
uct is elevated suggests that the micro-environment of the
DNA is more oxidising than usual [30], in keeping with
many other observations on diabetic subjects [1^4,31]. In
agreement with our data, the salicylate hydroxylation method
[32,33] has been used to trap OHcs in diabetic patients [34]
and our data show that such radicals are causing considerable
damage, to DNA at least.
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